Antibody Mediated Rejection in Heart Transplantation
Antibody Mediated Rejection in Heart Transplantation
Antibody Mediated Rejection in Heart Transplantation
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
PERCENTAGE OF ADULT HEART TRANSPLANT RECIPIENTS<br />
EXPERIENCING REJECTION BETWEEN TRANSPLANT DISCHARGE AND 1-YEAR FOLLOW-UP<br />
Stratified by Ma<strong>in</strong>tenance Immunosuppression (Follow-ups: July 1, 2004 - June 30, 2008)<br />
% experienc<strong>in</strong>g rejection with<strong>in</strong> 1 year<br />
60 Cyclospor<strong>in</strong>e + MMF, Treatment Cyclospor<strong>in</strong>e + MMF, No Treatment<br />
Tacrolimus + MMF, Treatment Tacrolimus + MMF, No Treatment<br />
50<br />
40<br />
30<br />
20<br />
10<br />
0<br />
Overall<br />
Overall: p < 0.0001<br />
18-44: p < 0.0001<br />
45-62: p < 0.0001<br />
Female: p = 0.007<br />
Male: p < 0.0001<br />
ISHLT<br />
18-44 45-62 63+ Female Male<br />
Cyclospor<strong>in</strong>e + MMF: N = 2,360<br />
Tacrolimus + MMF: N = 3,065<br />
NOTE: There were 149 patients with cyclospor<strong>in</strong>e+AZA and 41 with<br />
tacrolimus+AZA. These groups were excluded due to small numbers.<br />
2009<br />
Analysis is limited to patients who were alive at the time of the follow-up<br />
Treated rejection = Recipient was reported to (1) have at least<br />
one acute rejection episode that was treated with an antirejection<br />
agent; or (2) have been hospitalized for rejection.<br />
No rejection = Recipient had (i) no acute rejection episodes<br />
and (ii) was reported either as not hospitalized for rejection or<br />
did not receive anti-rejection agents.
Change language